Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (Ad-70, Dox-Oxd). Dextran 40 therapy made safer by pretreatment with dextran 1. Use of dextran nanoparticle: a paradigm shift in bacterial exopolysaccharide based biomedical applications. Sugar based biopolymers in nanomedicine new emerging era for cancer imaging and therapy. Anaphylactoid reactions to dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004. Immunoglobulin class and subclass distribution of dextran‐reactive antibodies in human reactors and non reactors to clinical dextran. Pathomechanisms of dextran-induced anaphylactoid/anaphylactic reactions in man. Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Exchange-mediated contrast in CEST and spin-lock imaging. A review of the efficacy and safety of 7.5% NaCl/6% dextran 70 in experimental animals and in humans. Initial evaluation of DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Effect of chelators on the pharmacokinetics of 99mTc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). 2-(3-ureido)-pen tanedioic acid, DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. The hydrodynamic radii of macromolecules and their effect on red blood cell aggregation. In vivo imaging of glucose uptake and metabolism in tumors. Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer. MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST). A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). PSMA specific antibodies and their diagnostic and therapeutic use. Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI. Synthesis and evaluation of GdIII‐based magnetic resonance contrast agents for molecular imaging of prostate‐specific membrane antigen. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Magnetic resonance molecular imaging of the HER-2/neu receptor. Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. Cancer cell targeting and imaging with biopolymer-based nanodevices. Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine? Clin. From these findings, it is possible that heparin-coated SPIO can be used as a good negative contrast agent in clinical MRI. From the results of in vitro cellular labeling, heparin-coated SPIO was more advantageous for cellular labeling because it could powerfully visualize the cells after a short incubation time (2 h). Both SPIO nanoparticles can be still suitable for T 2-weighted MRI because r 2 /r 1 ratio was >10. The reason was that the heparin-coated had a lower r 2/ r 1 ratio (18.2) at 1.5-T magnetic resonance imaging (MRI) compared to dextran-coated SPIO ( r 2/ r 1 ratio 32.9). In addition, the heparin-coated SPIO showed higher hyponegativity than dextran-coated SPIO. The zeta potential of heparin-coated SPIO was caused by the rich sulfonate group of heparin. The Zeta potential of non-coated SPIO was approximatelt −44 mV, whereas dextran-coated or heparin-coated SPIO was −6.4 and −33.5 mV, respectively. The zeta potential of the SPIO surface was detected to confirm the polymer coating. Compared to the uncoated SPIO, the heparin or dextran coating provided a better dispersion of SPIO nanoparticles in solution. The size of the crystalline core was adjusted to provide suitable relaxometric properties. Dextran-coated SPIO, which is commercially available as Feridex®, was prepared for the control group. In this study a potential magnetic resonance (MR) T 2 contrast agent was developed systematically based on heparin-coated superparamagnetic iron oxide (SPIO) nanoparticles.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |